Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURSUIT panitumumab rechallenge in ctDNA-selected metastatic colorectal cancer
jRCTs031190096Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab and irinotecan in colorectal cancer (CRC), sponsored by Takeda. Primary endpoint: Objective response rate. Started Dec 2019; status: completed.
02
Drugs
panitumumabirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031190096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190096.